Adaptimmune Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2014
Net Income	-113.87	-165.46	-158.09	-130.09	-137.17	Upgrade
Depreciation & Amortization	9.84	6.08	6.57	7.59	8.01	Upgrade
Share-Based Compensation	11.77	18.24	20.63	10.41	11.05	Upgrade
Other Operating Activities	-48.62	-0.63	141.62	58.49	5.6	Upgrade
Operating Cash Flow	-140.88	-141.77	10.73	-53.59	-112.51	Upgrade
Capital Expenditures	-4.68	-29.5	-8.57	-2.34	-1.59	Upgrade
Acquisitions	45.26	0	0	0	0	Upgrade
Change in Investments	135.03	118.88	84.58	-276.02	98.02	Upgrade
Other Investing Activities	0.93	-0.24	-0.21	-0.57	-1.48	Upgrade
Investing Cash Flow	176.54	89.14	75.8	-278.92	94.95	Upgrade
Share Issuance / Repurchase	0.88	12.87	3.29	340.05	0.37	Upgrade
Financing Cash Flow	0.88	12.87	3.29	340.05	0.37	Upgrade
Exchange Rate Effect	0.88	-2.3	0.37	-0.96	-0.37	Upgrade
Net Cash Flow	37.42	-42.06	90.18	6.58	-17.57	Upgrade
Free Cash Flow	-145.56	-171.27	2.16	-55.93	-114.1	Upgrade
Free Cash Flow Margin	-241.47%	-630.86%	35.05%	-1413.14%	-10169.25%	Upgrade
Free Cash Flow Per Share	-0.72	-1.06	0.01	-0.39	-1.09	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).